Evidence map›Paper›PMID 40671864›Full record

ArticleRespiratory medicine case reports2025

Sarcomatoid diffuse pleural mesothelioma in an 80-year-Old woman with long-term response to nivolumab plus ipilimumab: A case report.

Yukiko Yoshida, Hidenori Mizugaki, Yuma Sato, Ken Kuwahara, Noriyuki Yamada, Hajime Asahina, Hiroshi Yokouchi, Yoshihiro Matsuno, Satoshi Oizumi

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yukiko YoshidaDepartment of Respiratory Medicine, NHO Hokkaido Cancer Center, Sapporo, Japan.
Hidenori MizugakiDepartment of Respiratory Medicine, NHO Hokkaido Cancer Center, Sapporo, Japan.
Yuma SatoDepartment of Respiratory Medicine, NHO Hokkaido Cancer Center, Sapporo, Japan.
Ken KuwaharaDepartment of Diagnostic Pathology, NHO Hokkaido Cancer Center, Sapporo, Japan.
Noriyuki YamadaDepartment of Respiratory Medicine, NHO Hokkaido Cancer Center, Sapporo, Japan.
Hajime AsahinaDepartment of Respiratory Medicine, NHO Hokkaido Cancer Center, Sapporo, Japan.
Hiroshi YokouchiDepartment of Respiratory Medicine, NHO Hokkaido Cancer Center, Sapporo, Japan.
Yoshihiro MatsunoDepartment of Diagnostic Pathology, NHO Hokkaido Cancer Center, Sapporo, Japan.
Satoshi OizumiDepartment of Respiratory Medicine, NHO Hokkaido Cancer Center, Sapporo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An 80-year-old woman presented to our hospital with the chief complaint of left lateral thoracic pain. Chest computed tomography showed multiple nodular lesions in the left pleura and massive left pleural effusion. Based on clinical findings, imaging, and thoracoscopic pleural biopsy, a diagnosis of sarcomatoid diffuse pleural mesothelioma clinical T2N0M0 Stage IB was made. We administered nivolumab plus ipilimumab as first-line treatment, which resulted in significant reduction of pleural lesions and complete resolution of pleural effusion after two courses. No immune-mediated adverse events except fever were observed. Treatment was discontinued after 16 courses, with no disease recurrence for more than 2 years following the initial treatment. This case suggests that nivolumab plus ipilimumab can be an effective treatment option for older adults with pleural mesothelioma who maintain a good performance status.

Indexed as

ImmunotherapyLong-term responseNivolumab plus ipilimumabOlder adult patientPleural mesothelioma

Identifiers

PMID40671864
PMCPMC12266553

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.